Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses evaluating pembrolizumab vs placebo in stage IIB or IIC melanoma.
Georgina V. Long, BSc, PhD, MBBS
Advertisement
Articles by Georgina V. Long, BSc, PhD, MBBS
Georgina V. Long, BSc, PhD, MBBS, chair of Melanoma Medical Oncology and Translational Research at the Melanoma Institute of Australia (MIA) and Royal North Shore Hospital, University of Australia, discusses the patients with melanoma who respond best to the combination of dabrafenib plus trametinib.
Advertisement
Latest Updated Articles
Dr. Long on Treating Melanoma With Dabrafenib Plus TrametinibNovember 16th 2016
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
4
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
5